Digging into the SECURE T2D publication data: diverse patients, powerful outcomes

Hosted by
Insulet employees, Nancy Hanna & Dena Gottesman

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes!

Time stamps

8:06 – Discover how the SECURE T2D study paved the way for the use of AID for people living with type 2 diabetes
13:17 – Omnipod 5 reduced A1C across diverse patients, with the more significant point drop in those with A1Cs greater than 9%
17:01 – Dr. Bajaj shares how his view of the ideal AID candidate has evolved- and why
23:06 – Explore Omnipod 5’s Custom Foods feature and its impact on T2 patients

 

See more episodes
1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%)

This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod® 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.